Grand Pharmaceutical Group Limited will hold its 2026 annual general meeting (AGM) on 5 June in Hong Kong, seeking shareholder approval for a series of capital-management mandates, director re-elections and a comprehensive bye-laws overhaul.

Key agenda items:

• Capital mandates – Issuance: Directors request authority to allot up to 20% of issued share capital, equivalent to 709.91 million shares, based on the 3.55 billion shares outstanding as at 25 April 2026. – Repurchase: A separate mandate would allow on-market buy-backs of up to 354.96 million shares, or 10% of shares in issue.

• Final dividend The board proposes a cash dividend of HK$0.169 per share for FY 2025. The register closes on 16 June 2026, with payment slated for 30 June 2026.

• Board composition Shareholders will vote on the re-election of Executive Director Zhou Chao and Independent Non-Executive Directors Hu Yebi and Pei Geng. Dr Pei, an INED since 2011, is subject to a separate resolution under Hong Kong’s nine-year independence guideline.

• Corporate governance updates A new set of bye-laws, aligned with Hong Kong’s paperless listing regime, electronic dissemination rules and treasury-share framework, is proposed to replace the existing version in full.

• Share structure and control Controlling shareholder Outwit Investments Limited owns 1.90 billion shares, or 53.42% of the company. Full utilisation of the 10% buy-back mandate would lift Outwit’s stake to 59.35%, breaching Hong Kong’s takeover threshold; the board states it has no current intention to trigger such an outcome.

Key dates: – AGM: 5 June 2026 (register closed 2–5 June) – Dividend record date: 16 June 2026 – Dividend payment: on or about 30 June 2026

All resolutions require ordinary majorities except the bye-laws adoption, which is a special resolution.